Last reviewed 2026-05-27 · How we verify

Rituximab-HDS

Gruppo Italiano Terapie Innovative nei Linfomi · Phase 3 active Small molecule Under review Quality 0/100

Rituximab-HDS is a Monoclonal antibody (anti-CD20) Small molecule drug developed by Gruppo Italiano Terapie Innovative nei Linfomi. It is currently in Phase 3 development for B-cell non-Hodgkin lymphoma (various subtypes), Lymphoid malignancies expressing CD20. Also known as: Rituximab supplemented high-dose sequential chemotherapy..

Rituximab-HDS is a high-dose formulation of rituximab, a chimeric monoclonal antibody that depletes B cells by binding to CD20 antigen.

Rituximab-HDS is a treatment for Diffuse Large B-Cell Lymphoma and B-cell Lymphomas, which involves binding to the B-lymphocyte antigen CD20. It is classified as a BINDING AGENT and functions as an antibody that targets CD20.

Likelihood of approval

61.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 3 boost +3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Rituximab-HDS
Also known as	Rituximab supplemented high-dose sequential chemotherapy.
Sponsor	Gruppo Italiano Terapie Innovative nei Linfomi
Drug class	Monoclonal antibody (anti-CD20)
Target	CD20
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

Rituximab targets CD20, a surface antigen expressed on B lymphocytes, leading to B-cell depletion through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. The HDS (high-dose schedule) variant uses intensified dosing to enhance therapeutic efficacy in lymphoid malignancies. This mechanism is particularly effective in B-cell non-Hodgkin lymphomas where CD20+ tumor cells are the primary target.

Approved indications

B-cell non-Hodgkin lymphoma (various subtypes)
Lymphoid malignancies expressing CD20

Common side effects

Infusion reactions
Neutropenia
Anemia
Thrombocytopenia
Infections
Fatigue

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rituximab-HDS CI brief — competitive landscape report
Rituximab-HDS updates RSS · CI watch RSS
Gruppo Italiano Terapie Innovative nei Linfomi portfolio CI

Frequently asked questions about Rituximab-HDS

What is Rituximab-HDS?

Rituximab-HDS is a Monoclonal antibody (anti-CD20) drug developed by Gruppo Italiano Terapie Innovative nei Linfomi, indicated for B-cell non-Hodgkin lymphoma (various subtypes), Lymphoid malignancies expressing CD20.

How does Rituximab-HDS work?

Rituximab-HDS is a high-dose formulation of rituximab, a chimeric monoclonal antibody that depletes B cells by binding to CD20 antigen.

What is Rituximab-HDS used for?

Rituximab-HDS is indicated for B-cell non-Hodgkin lymphoma (various subtypes), Lymphoid malignancies expressing CD20.

Who makes Rituximab-HDS?

Rituximab-HDS is developed by Gruppo Italiano Terapie Innovative nei Linfomi (see full Gruppo Italiano Terapie Innovative nei Linfomi pipeline at /company/gruppo-italiano-terapie-innovative-nei-linfomi).

Is Rituximab-HDS also known as anything else?

Rituximab-HDS is also known as Rituximab supplemented high-dose sequential chemotherapy..

What drug class is Rituximab-HDS in?

Rituximab-HDS belongs to the Monoclonal antibody (anti-CD20) class. See all Monoclonal antibody (anti-CD20) drugs at /class/monoclonal-antibody-anti-cd20.

What development phase is Rituximab-HDS in?

Rituximab-HDS is in Phase 3.

What are the side effects of Rituximab-HDS?

Common side effects of Rituximab-HDS include Infusion reactions, Neutropenia, Anemia, Thrombocytopenia, Infections, Fatigue.

What does Rituximab-HDS target?

Rituximab-HDS targets CD20 and is a Monoclonal antibody (anti-CD20).

Drug class: All Monoclonal antibody (anti-CD20) drugs
Target: All drugs targeting CD20
Manufacturer: Gruppo Italiano Terapie Innovative nei Linfomi — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for B-cell non-Hodgkin lymphoma (various subtypes)
Indication: Drugs for Lymphoid malignancies expressing CD20
Also known as: Rituximab supplemented high-dose sequential chemotherapy.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing